Advertisement
Screener

OPKO Health, Inc. (OPK) ROE

OPKO HEALTH, INC. ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • OPKO HEALTH, INC. roe for the quarter ending 2026-06-30 was -6.16%, a change of 7.50% year-over-year.
  • OPKO HEALTH, INC. roe for the quarter ending 2026-03-31 was -17.68%, a change of -14.70% year-over-year.
  • OPKO HEALTH, INC. roe for the quarter ending 2025-12-31 was -17.80%, a change of -13.90% year-over-year.
  • OPKO HEALTH, INC. roe for the quarter ending 2025-09-30 was -13.82%, a change of -4.29% year-over-year.
  • OPKO HEALTH, INC. roe for fiscal 2025 was -17.80%, a change of -13.90% from fiscal 2024.
  • OPKO HEALTH, INC. roe for fiscal 2024 was -3.90%, a change of 9.70% from fiscal 2023.
  • OPKO HEALTH, INC. roe for fiscal 2023 was -13.59%, a change of 7.43% from fiscal 2022.
  • OPKO HEALTH, INC. roe for fiscal 2022 was -21.03%, a change of -19.24% from fiscal 2021.
Available history
2009-12-31 to 2026-06-30
Data captured

Historical ROE

DateROENet income 12 monthNet income 3 monthShareholder equity
2026-06-30-6.16%-$72.89M-$8.42M$1.18B
2026-03-31-17.68%-$212.92M-$54.85M$1.2B
2025-12-31-17.80%-$225.68M-$31.26M$1.27B
2025-09-30-13.82%-$180.4M$21.63M$1.31B
2025-06-30-13.66%-$177.14M-$148.44M$1.3B
2025-03-31-2.97%-$39M-$67.61M$1.31B
2024-12-31-3.90%-$53.22M$14.03M$1.37B
2024-09-30-9.53%-$133.73M$24.89M$1.4B
2024-06-30-17.42%-$243.1M-$10.30M$1.4B
2024-03-31-20.15%-$252.43M-$81.84M$1.25B
2023-12-31-13.59%-$188.86M-$66.48M$1.39B
2023-09-30-14.37%-$207.61M-$84.47M$1.44B
2023-06-30-13.63%-$209.23M-$19.64M$1.54B
2023-03-31-18.77%-$291.24M-$18.27M$1.55B
2022-12-31-21.03%-$328.41M-$85.23M$1.56B
2022-09-30-19.46%-$316.95M-$86.09M$1.63B
2022-06-30-11.76%-$202.12M-$101.65M$1.72B
2022-03-31-7.22%-$116.65M-$55.43M$1.61B
2021-12-31-1.79%-$30.14M-$73.78M$1.69B
2020-12-311.83%$30.59M$32.30M$1.67B
2019-12-31-19.50%-$314.93M-$112.35M$1.61B
2018-12-31-8.54%-$153.04M-$76.07M$1.79B
2014-12-31-20.38%-$171.67M-$52.97M$842.14M
2014-09-30-15.17%-$135.5M-$48.67M$893.26M
2014-06-30-16.01%-$146.83M-$25.48M$917.39M
2014-03-31-14.94%-$124.74M-$44.55M$835.22M
2013-12-31-13.05%-$114.41M-$16.80M$876.41M
2013-09-30-11.27%-$98.16M-$60.00M$870.73M
2013-06-30-15.20%-$47.8M-$3.39M$314.48M
2013-03-31-17.04%-$54.65M-$34.22M$320.82M
2012-12-31-16.19%-$29.05M-$548.00K$179.39M
2012-09-30-6.90%-$10.1M-$9.65M$146.27M
2012-06-30-5.74%-$8.69M-$10.24M$151.5M
2012-03-31-2.70%-$4.19M-$8.61M$154.98M
2011-12-31-0.80%-$1.28M$18.40M$160.88M
2011-09-30-19.87%-$20.36M-$8.24M$102.48M
2011-06-30-17.52%-$19.48M-$5.75M$111.16M

Annual ROE

DateROENet income 12 monthShareholder equity
2025-12-31-17.80%-$225.68M$1.27B
2024-12-31-3.90%-$53.22M$1.37B
2023-12-31-13.59%-$188.86M$1.39B
2022-12-31-21.03%-$328.41M$1.56B
2021-12-31-1.79%-$30.14M$1.69B
2020-12-311.83%$30.59M$1.67B
2019-12-31-19.50%-$314.93M$1.61B
2018-12-31-8.54%-$153.04M$1.79B
2017-12-31-16.56%-$305.25M$1.84B
2016-12-31-2.36%-$48.36M$2.05B
2015-12-31-1.50%-$30.03M$2B
2014-12-31-20.38%-$171.67M$842.14M
2013-12-31-13.05%-$114.41M$876.41M
2012-12-31-16.19%-$29.05M$179.39M
2011-12-31-0.80%-$1.28M$160.88M
2010-12-31-82.10%-$18.93M$23.05M
2009-12-31-95.30%-$30.11M$31.6M

Similar stocks

Stock NameCountryMarket CapPE Ratio
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
HARROW, INC. (HROW)United States$1.240B-42.77
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
Jaguar Health, Inc. (JAGX)United States$1.184B
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Avalyn Pharma Inc. (AVLN)United States$1.267B
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93